Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinlarebant in Stargardt Disease in Adolescent Subjects
NCT05244304Phase 3Completed
- Sponsor
- Belite Bio, Inc
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of tinlarebant, sponsored by Belite Bio, Inc. Started Mar 2022; status: completed.
02
Drugs
tinlarebant
Beyond the preview
Go deeper on NCT05244304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244304.